LRX712 / Novartis - LARVOL DELTA

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2 | N=45 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2 | N=45 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Osteoarthritis • Pain • Rheumatology

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=45; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial primary completion date: Jan 2024 ➔ Jul 2023

Clinical • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=45; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: May 2023 ➔ Jan 2024; Trial primary completion date: May 2023 ➔ Jan 2024

Clinical • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: Novartis Pharmaceuticals; Suspended ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=40; Suspended; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Suspended

Clinical • Trial suspension • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: Novartis Pharmaceuticals; N=26 ➔ 40; Trial completion date: Feb 2021 ➔ Jan 2022; Initiation date: Dec 2019 ➔ Mar 2020; Trial primary completion date: Feb 2021 ➔ Jan 2022

Clinical • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=26; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • New P2 trial • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Jan 2022 ➔ Apr 2022; Initiation date: Mar 2020 ➔ Jul 2020; Trial primary completion date: Jan 2022 ➔ Apr 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Osteoarthritis • Pain • Rheumatology • MRI

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Jun 2022 ➔ Sep 2022; Trial primary completion date: Jun 2022 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients (clinicaltrials.gov) - P1; N=42; Completed; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Completed; N=30 ➔ 42

Clinical • Enrollment change • Trial completion